Current problems in cancer · 2026
Multicenter retrospective study on the clinical profiles of patients with extensive-stage small-cell lung cancer who met the eligibility criteria for clinical trials.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yazaki Tatsuya, Sonehara Kei, Tsutsui Toshiharu, Nozawa Shuhei, Agatsuma Toshihiko, Yamamoto Manabu, Matsuo Akemi, Nakanishi Masanori, Chiaki Tomoshige, Kato Akane, Miyahara Takashige, Hachiya Tsutomu, Kanda Shintaro, Hanaoka Masayuki
Аннотация
BACKGROUND: Chemoimmunotherapy is the standard first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC); however, a limited number of real-world cases meet the inclusion and exclusion criteria of clinical trials. This study investigated whether chemoimmunotherapy is selected in patients with ES-SCLC who meet eligibility criteria in real-world practice and identified their clinical characteristics.
METHODS: A total of 198 patients diagnosed with ES-SCLC received first-line treatment at 11 institutions between August 2019 and June 2023. We evaluated the efficacy and safety of first-line treatment in patients meeting the eligibility criteria of the IMpower133 and CASPIAN trials. This multicenter retrospective study included 78 patients (39.4%) who met the eligibility criteria.
RESULTS: Fifty-six (71.8%) and twenty-two (28.2%) underwent chemoimmunotherapy and chemotherapy, respectively. The proportion of patients aged ≥75 years was higher in the chemotherapy group. The median progression-free survival in the chemoimmunotherapy and chemotherapy groups was 5.1 versus 4.6 months (hazard ratio [HR] 0.50; 95% confidence interval [CI], 0.29-0.84), respectively. The median overall survival in the chemoimmunotherapy and chemotherapy groups was 17.1 versus 9.4 months (HR 0.51; 95% CI, 0.29-0.88), respectively. The discontinuation rate of treatment-related adverse events did not differ significantly between the two groups (5.4% vs. 0.0%, p = 0.555).
CONCLUSION: First-line chemoimmunotherapy is considered a valuable treatment option for patients with ES-SCLC who meet the eligibility criteria for clinical trials. However, even among eligible patients, chemotherapy alone may be selected based on various reasons, such as older age. Furthermore, a comprehensive analysis of real-world data is required.
TRIAL REGISTRATION: This study was registered in the UMIN Clinical Trial Registry (A multicenter retrospective study to evaluate the efficacy and safety of platinum-based chemotherapy in combination with immunotherapy for extensive-stage small cell lung cancer in the real-world setting, UMIN000053134).
METHODS: A total of 198 patients diagnosed with ES-SCLC received first-line treatment at 11 institutions between August 2019 and June 2023. We evaluated the efficacy and safety of first-line treatment in patients meeting the eligibility criteria of the IMpower133 and CASPIAN trials. This multicenter retrospective study included 78 patients (39.4%) who met the eligibility criteria.
RESULTS: Fifty-six (71.8%) and twenty-two (28.2%) underwent chemoimmunotherapy and chemotherapy, respectively. The proportion of patients aged ≥75 years was higher in the chemotherapy group. The median progression-free survival in the chemoimmunotherapy and chemotherapy groups was 5.1 versus 4.6 months (hazard ratio [HR] 0.50; 95% confidence interval [CI], 0.29-0.84), respectively. The median overall survival in the chemoimmunotherapy and chemotherapy groups was 17.1 versus 9.4 months (HR 0.51; 95% CI, 0.29-0.88), respectively. The discontinuation rate of treatment-related adverse events did not differ significantly between the two groups (5.4% vs. 0.0%, p = 0.555).
CONCLUSION: First-line chemoimmunotherapy is considered a valuable treatment option for patients with ES-SCLC who meet the eligibility criteria for clinical trials. However, even among eligible patients, chemotherapy alone may be selected based on various reasons, such as older age. Furthermore, a comprehensive analysis of real-world data is required.
TRIAL REGISTRATION: This study was registered in the UMIN Clinical Trial Registry (A multicenter retrospective study to evaluate the efficacy and safety of platinum-based chemotherapy in combination with immunotherapy for extensive-stage small cell lung cancer in the real-world setting, UMIN000053134).